New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market ...

Shares of Spark Therapeutics Inc. (ONCE) saw a handy gain to close out the week after the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee unanimously ...

It’s been almost a year since Spark Therapeutics won a groundbreaking gene therapy approval in the U.S. for Luxturna, and now its marketing partner Novartis has done the same across the pond. The ...

Biomedicine just took a giant step forward in the U.S. This week, the U.S. Food and Drug Administration approved Luxturna, a form of gene therapy that seeks to treat retinal dystrophy, a rare eye ...

The Food and Drug Administration has approved Spark Therapeutics' Luxturna. The treatment would help those with Leber congenital amaurosis, a rare genetic retinal disease. It's specifically approved ...

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness Spark Therapeutics set the price for the gene therapy at $425,000 per eye A one-time treatment with Luxturna, the ...

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates ...

At a time when rare disease drugmakers routinely strike up criticism with their pricing decisions, Spark Therapeutics is surely prepping a pitch for its newly approved Luxturna. On Tuesday, the FDA ...

The meeting could determine whether the two young siblings would keep going blind. The doctor knew that going in, but he was feeling good. He’d negotiated huge discounts before, allowing patients to ...

PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, ...